Chiasma is a biopharma company focused on creating new drug products by marrying its proprietary technology to approved drugs. This enables drugs to be switched from injectable to oral, but importantly can also result in new indications or improved labels by reducing side effects.

The Company’s Transient Permeability Enhancer (TPE) technology promotes the oral delivery of drugs. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed, which can have the salutary effect of lowering cost of goods sold.